USE OF THE FL-ONE HUNDRED EIGHTEEN CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL-ONE HUNDRED EIGHTEEN DERIVATIVES FOR TREATMENT OF HUMAN DISEASE
申请人:Canget Bio Tekpharma, LLC
公开号:US20180170944A1
公开(公告)日:2018-06-21
Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.